secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2026-08-19T12:50:32+00:00
Accession:  0001493152-26-039140
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INBS reports FY2026 revenue up 38% to $4.2M; gross margin expands to 48.63%
---------------------------------------------------------------------------

- FY2026 revenue $4.2M, up 38% YoY from $3.05M; gross profit $2.05M, up 64% YoY.
- Gross margin 48.63%, up 778 bps from 40.85%; driven by Syrma Johari manufacturing transition.
- Reader installed base 1,886 units (+22% YoY); consumable cartridges 106,500 (+35%); 502 active customers.
- FDA 510(k) submission on track for H2 calendar 2026; all clinical data collection completed.
- New strategic partnership with Bouygues UK for drug-testing rollout; eighth European patent granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/0001493152-26-039140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer